Showing 3871-3880 of 5623 results for "".
- Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DMEhttps://modernod.com/news/alimera-completes-recruitment-for-its-landmark-new-day-study/2481633/Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in p
- iHealthScreen Announces FDA 510(k) Submission for iPredict Automated AI-Based AMD Toolhttps://modernod.com/news/ihealthscreen-announces-fda-510k-submission-for-ipredict-automated-ai-based-amd-tool/2481632/iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company to apply for an FDA clearance for screening AMD, according to a company news release. iPredict AI Eye Screening System provides fully automated age-related macular degener
- Partnership Agreement Between Mireca and Graybug Terminatedhttps://modernod.com/news/partnership-agreement-between-mireca-and-graybug-terminated/2481631/Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases. As part of the termination, all intellectual property rights that
- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem Cellshttps://modernod.com/news/nei-scientists-publish-recipe-for-making-blood-vessel-cells-from-patient-stem-cells/2481626/Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. &ldquo
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo
- Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapieshttps://modernod.com/news/ray-therapeutics-closes-oversubscribed-100m-series-a-financing-to-advance-optogenetic-gene-therapies/2481621/Ray Therapeutics announced an upsized and oversubscribed $100 million Series A financing round to advance multiple programs targeting blinding diseases through clinical development. Ray Therapeutics has developed an optogenetic platform to bioengineer a pipeline of g
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- Market Scope: Improved Vitrectomy Machine Features Expected to Expand Retinal Treatmentshttps://modernod.com/news/market-scope-improved-vitrectomy-machine-features-expected-to-expand-retinal-treatments/2481617/Advancements in vitrectomy machine technology are expected to improve safety and efficacy and enable surgeons to reach a larger population of patients with retinal disease over the next 5 years, according to a Market Scope report. These advancements include small-incision vitrectomy, subretinal t
- Researchers Discover Small-Molecule Drugs with Potential Clinical Utility in the Treatment of Retinal Diseaseshttps://modernod.com/news/researchers-discovere-small-molecule-drugs-with-potential-clinical-utility-in-the-treatment-of-retinal-diseases/2481616/In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). The study, titled, “
- C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrackhttps://modernod.com/news/c-light-receives-fda-clearance-for-retinal-eye-movement-monitor-retitrack/2481615/C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals. The